Terns Announces Initiation of Patient Dosing in Aviation Phase Ib Nash Clinical Trial of Vap-1 Inhibitor Tern-201

Terns Pharmaceuticals, Inc. announced the initiation of patient dosing in the AVIATION Trial, a Phase Ib clinical trial evaluating TERN-201, an orally-administered, highly selective inhibitor of vascular adhesion protein-1 (VAP-1) in patients with NASH.